Monovaccine (Epstein - Barr virus) Market by Application (Mononucleosis, Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, and Nasopharyngeal Carcinoma) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Published In : May 2019

Code : CMI2002

Pages :84

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

North America and Europe are expected to be a potential regions for monovaccines in future

High prevalence of Epstein-Barr virus infection and disease associated with it is expected to propel growth of the global monovaccine (Epstein-Barr virus) market. According to data published by Centers for Disease Control and Prevention (CDC) in 2018, Epstein-Barr virus (EBV) is one of the most common human viruses. According to the same source, in the U.S., it was estimated that around nine out of ten adults have antibodies that show that they have a current or past EBV infection.

The number of research and development activities for development of novel monovaccines in Europe are growing in frequency.

For instance, in March 2017, Cancer Research U.K. completed its phase 1b of clinical trials of Modified Vaccinia Ankara (MVA-EBNA1/LMP2) vaccine. It is being used to treat nasopharyngeal cancer patients with positive Epstein-Barr virus infection.

In January 2019, researchers and scientists from the German Cancer Research Center developed a new strategy for a vaccine that targets different EBV virus life phases and has potential to provide effective protection against EBV infection.

Such, initiatives from several organizations for development of novel monovaccines (Epstein - Barr virus) are expected to spur interest of key players to invest in R&D activities.